Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.

Hartmaier RJ, Albacker LA, Chmielecki J, Bailey M, He J, Goldberg ME, Ramkissoon S, Suh J, Elvin JA, Chiacchia S, Frampton GM, Ross JS, Miller V, Stephens PJ, Lipson D.

Cancer Res. 2017 May 1;77(9):2464-2475. doi: 10.1158/0008-5472.CAN-16-2479. Epub 2017 Feb 24.

2.

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V.

Mol Cancer Ther. 2018 Jul;17(7):1595-1601. doi: 10.1158/1535-7163.MCT-17-1107. Epub 2018 Apr 13.

3.

Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.

Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim JI.

BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1.

4.

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.

Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V.

Oncotarget. 2017 Jun 13;8(24):39254-39267. doi: 10.18632/oncotarget.16845.

5.

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS.

Oncologist. 2015 Oct;20(10):1132-9. doi: 10.1634/theoncologist.2015-0156. Epub 2015 Sep 2.

6.

Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.

Paolillo C, Londin E, Fortina P.

Scand J Clin Lab Invest Suppl. 2016;245:S84-91. doi: 10.1080/00365513.2016.1210331. Epub 2016 Aug 17.

PMID:
27542004
7.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.

Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M.

Breast Cancer Res Treat. 2015 Nov;154(1):155-62. doi: 10.1007/s10549-015-3592-z. Epub 2015 Oct 12.

PMID:
26458824
8.

Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.

Ross JS, Wang K, Rand JV, Sheehan CE, Jennings TA, Al-Rohil RN, Otto GA, Curran JC, Palmer G, Downing SR, Yelensky R, Lipson D, Balasubramanian S, Garcia L, Mahoney K, Ali SM, Miller VA, Stephens PJ.

Am J Surg Pathol. 2014 Feb;38(2):235-8. doi: 10.1097/PAS.0000000000000102.

PMID:
24418857
9.

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.

Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J.

Genome Med. 2017 Feb 24;9(1):16. doi: 10.1186/s13073-017-0408-2.

10.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.

11.

The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.

Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM.

Hum Genomics. 2016 Jan 16;10:4. doi: 10.1186/s40246-016-0061-7.

12.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VA.

Oncologist. 2015 May;20(5):499-507. doi: 10.1634/theoncologist.2014-0378. Epub 2015 Apr 16.

13.

Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.

Saunus JM, Quinn MC, Patch AM, Pearson JV, Bailey PJ, Nones K, McCart Reed AE, Miller D, Wilson PJ, Al-Ejeh F, Mariasegaram M, Lau Q, Withers T, Jeffree RL, Reid LE, Da Silva L, Matsika A, Niland CM, Cummings MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Anderson MJ, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Taylor D, Waddell N, Wood S, Xu Q, Kassahn KS, Narayanan V, Taib NA, Teo SH, Chow YP, kConFab, Jat PS, Brandner S, Flanagan AM, Khanna KK, Chenevix-Trench G, Grimmond SM, Simpson PT, Waddell N, Lakhani SR.

J Pathol. 2015 Nov;237(3):363-78. doi: 10.1002/path.4583. Epub 2015 Aug 19.

PMID:
26172396
14.

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L.

Oncologist. 2016 Sep;21(9):1063-78. doi: 10.1634/theoncologist.2015-0369. Epub 2016 Jul 6. Review.

15.

Comparative genomic analysis of primary tumors and metastases in breast cancer.

Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, Monneur A, Charafe-Jauffret E, Goncalves A, Viens P, Birnbaum D, Chaffanet M.

Oncotarget. 2016 May 10;7(19):27208-19. doi: 10.18632/oncotarget.8349.

16.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

17.

Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.

Glinsky GV.

Cancer Lett. 2016 Oct 10;381(1):176-93. doi: 10.1016/j.canlet.2016.08.001. Epub 2016 Aug 3.

PMID:
27497790
18.

Genomics-Enabled Precision Medicine for Cancer.

Roos A, Byron SA.

Cancer Treat Res. 2019;178:137-169. doi: 10.1007/978-3-030-16391-4_5.

PMID:
31209844
19.

Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.

San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H.

Ann Oncol. 2016 Apr;27(4):635-41. doi: 10.1093/annonc/mdv604. Epub 2015 Dec 17.

20.

PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.

Piñeiro-Yáñez E, Reboiro-Jato M, Gómez-López G, Perales-Patón J, Troulé K, Rodríguez JM, Tejero H, Shimamura T, López-Casas PP, Carretero J, Valencia A, Hidalgo M, Glez-Peña D, Al-Shahrour F.

Genome Med. 2018 May 31;10(1):41. doi: 10.1186/s13073-018-0546-1.

Supplemental Content

Support Center